POLB Stock Overview
Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.073 |
| 52 Week High | UK£0.16 |
| 52 Week Low | UK£0.07 |
| Beta | 2.14 |
| 1 Month Change | -11.45% |
| 3 Month Change | -27.23% |
| 1 Year Change | -18.78% |
| 3 Year Change | -20.54% |
| 5 Year Change | n/a |
| Change since IPO | -31.63% |
Recent News & Updates
Recent updates
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth
Aug 20
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Shareholder Returns
| POLB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 2.1% | -0.9% | -1.4% |
| 1Y | -18.8% | -0.6% | 4.6% |
Return vs Industry: POLB underperformed the UK Pharmaceuticals industry which returned -1% over the past year.
Return vs Market: POLB underperformed the UK Market which returned 17.5% over the past year.
Price Volatility
| POLB volatility | |
|---|---|
| POLB Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: POLB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: POLB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Poolbeg Pharma PLC Fundamentals Summary
| POLB fundamental statistics | |
|---|---|
| Market cap | UK£36.75m |
| Earnings (TTM) | -UK£4.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.4x
P/E RatioIs POLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.38m |
| Earnings | -UK£4.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0088 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did POLB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 07:26 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poolbeg Pharma PLC is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Brian White | Shore Capital Group Ltd |